Leqembi & Health Equity

This episode is brought to you by Semafor Healthcare.Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.Listen to Health Affairs Ryann Tanap and Vabren Watts in the first of many "Health Equity Corner" episodes on This Week discuss the latest from the health equity department and unpack what Leqembi, the newly approved Alzheimer's disease drug, could mean in the health equity space.Related Links:FDA Grants Accelerated Approval for Alzheimer's Disease Treatment (FDA)CMS Statement on FDA Accelerated Approval of LecanemabA New Alzheimer's Drug Will Cost $26,500 A Year. Who Will Be Able To Get It? (NBC News)Health Affairs Racism and Health Theme IssueHealth Affairs FellowshipsCurrently, more than 70 percent of our content is freely available — and we’d like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone. Subscribe to Semafor Healthcare for free.